Optim.AI™ is a combinatorial multi-drug sensitivity test that predicts the most effective treatment options for each individual cancer patients using limited fresh tumor tissue.
Optim.AI™ is a revolutionary technology that efficiently predicts drug sensitivity by combining biological experiments with the power of artificial intelligence.
Unbiased, faster, and more precise treatment selection
for cancer patients
Using only the patient’s own data as both input and control, with no reliance on external data
Total predictive value: % of true positives and true negative predictions
including single, 2-, 3- and 4-drug combinations for each patient
for samples that pass our quality acceptance criteria
fast turn-around-time
Experience with 25+ cancer types
Sahib et al, Cancer Med (2024); Lee et al, JCO Precis Oncol (2025); Chan et al, npj Precis Onc (2025); Rashid et al, Cancer Res (2026); Ho et al, HemaSphere (2026)
A detailed, patient-specific, sensitivity profile that stratifies Standard-of-Care and evidence-based treatment options from the custom 12-drug panel selected by the clinician.
The report contains all single and top ranking 2-, 3- and 4-drug combinations ranked by the Normalized Cell Viability (NCV) score. The NCV quantifies cell killing from 0 to 1+, where 0 indicates all cancer cells are killed, predicting high sensitivity to treatment.
Annotations
* Optim.AI™ requires a blast count in the blood to be able to use a blood sample for testing.
